Helicobacter pylori is the primary etiologic agent involved in gastric diseases in humans with worldwide distributions. In 2005, H. pylori was identified as a microbiologic contaminant of water, and its role in gastric diseases was further assessed.
Helicobacter pylori is a putative risk factor for peptic ulcers and gastric cancer. Current treatment guidelines for H pylori are based on results from developed countries.
In Guatemala, gastric cancer (GC) presents some of the highest rates of incidence and mortality in the world.
Despite decreasing global incidence trends, gastric cancer is still among the five most incident cancers in the world and the third cancer-related cause of death.
Serum pepsinogen 2 (sPG2) level is one of the predictive parameters for gastric cancer (GC) risk but factors that regulate change in PG2 expression are still unknown. Aim of the present study was to investigate genetic variants that may regulated PG2 expression in patients with GC or at risk for GC.
Chile has a 60 to 80 % rate of Helicobacter infection depending on the region; is no surprise that the mortality rate due to gastric cancer in Chile is one of the highest in America.
